MX360640B - Diagnosis e imagenologia de cancer. - Google Patents

Diagnosis e imagenologia de cancer.

Info

Publication number
MX360640B
MX360640B MX2012010119A MX2012010119A MX360640B MX 360640 B MX360640 B MX 360640B MX 2012010119 A MX2012010119 A MX 2012010119A MX 2012010119 A MX2012010119 A MX 2012010119A MX 360640 B MX360640 B MX 360640B
Authority
MX
Mexico
Prior art keywords
imaging
mammal
cell cycle
cancer diagnosis
administering
Prior art date
Application number
MX2012010119A
Other languages
English (en)
Other versions
MX2012010119A (es
Inventor
S Gray Lloyd
Original Assignee
Tau Therapeutics Llc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tau Therapeutics Llc Star filed Critical Tau Therapeutics Llc Star
Publication of MX2012010119A publication Critical patent/MX2012010119A/es
Publication of MX360640B publication Critical patent/MX360640B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para crear imagen de una enfermedad o condición en un mamífero, que incluye los pasos de: administrar una cantidad terapéuticamente efectiva de un inhibidor de ciclo celular para detener efectivamente la proliferación de células eucarióticas en un punto de control del ciclo celular entre las fases G1 y S, detener la administración del inhibidor de ciclo celular durante un periodo, administrar un marcador el mamífero y crear imagen del mamífero.
MX2012010119A 2010-03-01 2011-02-28 Diagnosis e imagenologia de cancer. MX360640B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30903010P 2010-03-01 2010-03-01
PCT/US2011/026416 WO2011109262A2 (en) 2010-03-01 2011-02-28 Cancer diagnosis and imaging

Publications (2)

Publication Number Publication Date
MX2012010119A MX2012010119A (es) 2012-09-12
MX360640B true MX360640B (es) 2018-11-09

Family

ID=44542787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010119A MX360640B (es) 2010-03-01 2011-02-28 Diagnosis e imagenologia de cancer.

Country Status (13)

Country Link
US (1) US9427429B2 (es)
EP (1) EP2542155B1 (es)
JP (1) JP6017964B2 (es)
KR (1) KR101821343B1 (es)
CN (1) CN102781316B (es)
AU (1) AU2011223883B2 (es)
CA (1) CA2787673A1 (es)
ES (1) ES2557407T3 (es)
IL (1) IL221035A0 (es)
MX (1) MX360640B (es)
SG (2) SG10201501496TA (es)
WO (1) WO2011109262A2 (es)
ZA (1) ZA201205377B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212127B2 (en) * 2004-08-20 2015-12-15 University Of Virginia Patent Foundation T type calcium channel inhibitors
MX360640B (es) 2010-03-01 2018-11-09 Tau Therapeutics Llc Star Diagnosis e imagenologia de cancer.
BR112019000499A2 (pt) * 2016-07-19 2019-04-24 Bristol-Myers Squibb Company radioligantes para imagiologia da enzima ido1
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3585376A4 (en) 2017-02-15 2020-11-25 Cavion, Inc. CALCIUM CHANNELS INHIBITORS
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219609A (en) 1968-07-19 1971-01-20 Koninklijke Pharma Fab Nv Diphenylmethoxyethylamino derivatives
US3732247A (en) 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
US4091103A (en) 1976-06-23 1978-05-23 Ciba-Geigy Corporation Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives
JPS59161392A (ja) 1983-03-04 1984-09-12 Nippon Shinyaku Co Ltd ジヒドロピリジン誘導体及びその製法
US4906646A (en) 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
FR2601366B1 (fr) 1986-07-10 1988-11-25 Andre Buzas Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant.
ATE128623T1 (de) 1988-08-02 1995-10-15 Nissan Chemical Ind Ltd Mittel zur verbesserung von arzneimitteleffekten für antitumormittel.
JP2850376B2 (ja) 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
FR2636946B1 (fr) 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0467435A3 (en) 1990-07-19 1992-04-01 Akzo N.V. Benzhydryl derivatives having calmodulin inhibitor properties
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6413967B1 (en) 1995-03-30 2002-07-02 The University Of Virginia Patents Foundation Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy
WO1997009055A1 (en) 1995-09-08 1997-03-13 Beth Israel Deaconess Medical Center Isolation of microdomains of caveolae and gpi-anchored proteins
ATE256110T1 (de) 1995-09-15 2003-12-15 Neurosearch As Piperindinverbindungen als calcium-kanal-blocker
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
US6191156B1 (en) 1997-04-11 2001-02-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating bladder dysfunction
US6703374B1 (en) * 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
JP2001525161A (ja) 1997-12-03 2001-12-11 メルク エンド カムパニー インコーポレーテッド 低電位で活性化されるカルシウムチャネル組成物と方法
WO1999029847A1 (en) 1997-12-05 1999-06-17 Loyola University Of Chicago T-type voltage-gated calcium channels and method of using same
JPH11246417A (ja) 1998-03-04 1999-09-14 Nissan Chem Ind Ltd 糖尿病性腎症治療用医薬組成物
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
WO2000015845A1 (en) * 1998-08-26 2000-03-23 South Alabama Medical Science Foundation T-type calcium channel
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6946475B1 (en) 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
ATE269848T1 (de) 1999-04-07 2004-07-15 Univ Virginia Calciumkanalblocker als antikrebsmittel
US7195783B2 (en) 1999-07-09 2007-03-27 Fx Life Sciences International Gmbh Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics
AU2001235363A1 (en) 2000-02-25 2001-09-03 Novo-Nordisk A/S Mibefradil analogues and their use
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
CA2415826A1 (en) 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004533449A (ja) * 2001-05-11 2004-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体
US20050032724A1 (en) 2001-07-23 2005-02-10 Gunther Heinrich Methods for improved treatment of cancer with irinotecan based on mrp1
DE60322509D1 (de) 2002-01-17 2008-09-11 Univ British Columbia Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
EP1506032A1 (en) 2002-05-20 2005-02-16 Research Development Foundation Aerosol drug inhibition of lung metastases
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10227511A1 (de) 2002-06-19 2004-01-08 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
JP2006502188A (ja) * 2002-09-17 2006-01-19 ニューヨーク ユニバーシティ 年齢関連記憶欠陥（ａａｍｉ）、中程度認識欠陥（ｍｃｉ）、および痴呆を細胞周期インヒビターで処置する方法
NZ542681A (en) 2003-03-28 2009-01-31 Nissan Chemical Ind Ltd T-type calcium channel blockers comprising optically active 1,4-dihydropyridines
TW200528107A (en) 2003-11-25 2005-09-01 Nissan Chemical Ind Ltd T-type calcium channel inhibitor
EP1730190A4 (en) 2004-02-11 2008-07-23 Univ Virginia INHIBITION OF CAV3 ISOFORMS AND THE & 25B SPLICE VARIATIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AU2011203315B8 (en) 2004-02-11 2012-02-16 University Of Virginia Patent Foundation Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer
US20070178462A1 (en) 2004-02-18 2007-08-02 Uebele Victor N Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
WO2006003020A1 (en) 2004-07-02 2006-01-12 L'oreal Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof
US9212127B2 (en) 2004-08-20 2015-12-15 University Of Virginia Patent Foundation T type calcium channel inhibitors
US20120264804A1 (en) 2004-08-20 2012-10-18 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
US20100222406A1 (en) 2007-09-11 2010-09-02 University Of Virginia Patent Foundation T Type Calcium Channel Blockers and the Treatment of Diseases
CA2576186A1 (en) 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
US7851431B2 (en) 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
JP5339291B2 (ja) * 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
CN101528768A (zh) * 2006-08-10 2009-09-09 肿瘤疗法科学股份有限公司 与乳腺癌相关的基因和多肽
CN103143017A (zh) 2006-12-19 2013-06-12 基因技术公司 用于辅助和新辅助疗法以及早期肿瘤的治疗的vegf特异性拮抗剂
CA2684938A1 (en) 2007-05-02 2008-11-13 Tau Therapeutics Llc Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
WO2008141189A1 (en) 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
CA2736564A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
JP5029328B2 (ja) 2007-12-05 2012-09-19 マツダ株式会社 自動車の前部車体構造
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
JP5806210B2 (ja) 2009-06-05 2015-11-10 ティーエーユー・セラピューティクス・エルエルシー 癌または前癌状態を治療するための組み合わせ方法
MX360640B (es) 2010-03-01 2018-11-09 Tau Therapeutics Llc Star Diagnosis e imagenologia de cancer.
MX2014002967A (es) 2011-09-12 2015-04-13 Tau Therapeutics Llc Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas.

Also Published As

Publication number Publication date
ZA201205377B (en) 2013-09-25
WO2011109262A2 (en) 2011-09-09
SG10201501496TA (en) 2015-04-29
MX2012010119A (es) 2012-09-12
EP2542155B1 (en) 2015-11-04
IL221035A0 (en) 2012-09-24
CA2787673A1 (en) 2011-09-09
AU2011223883A1 (en) 2012-09-13
JP6017964B2 (ja) 2016-11-02
KR20130014506A (ko) 2013-02-07
WO2011109262A3 (en) 2011-11-17
CN102781316A (zh) 2012-11-14
HK1179143A1 (zh) 2013-09-27
EP2542155A2 (en) 2013-01-09
US20120321561A1 (en) 2012-12-20
US9427429B2 (en) 2016-08-30
ES2557407T3 (es) 2016-01-25
AU2011223883B2 (en) 2015-10-08
KR101821343B1 (ko) 2018-01-23
JP2013521287A (ja) 2013-06-10
EP2542155A4 (en) 2013-07-17
CN102781316B (zh) 2016-07-06
SG183114A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
MX360640B (es) Diagnosis e imagenologia de cancer.
WO2013033396A3 (en) Fap-activated proteasome inhibitors for treating solid tumors
MX2014005122A (es) Inhibidores de la recirculacion de acidos biliares para el tratamiento de hipercolemia y enfermedad hepatica colestasica.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
WO2014144650A3 (en) Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
LT3023102T (lt) Ibat inhibitoriai, skirti kepenų ligų gydymui
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2015019284A3 (en) Inhibition of cxcr4 signaling in cancer immunotherapy
MX2019013263A (es) Inhibidores de la recirculacion de acidos biliares para el tratamiento de enfermedades hepaticas colestasicas pediatricas.
IL223889B (en) Contrasting side effects associated with the administration of an anti-hyaluronan factor and methods for alleviating or preventing the side effects
MX344725B (es) Metodo entrelazado para tratar cancer o una condicion precancerosa.
GB2451987A (en) Assessment of the effects of topical administration of chemodenervating pharmaceuticals
PH12014500990A1 (en) Methods for treating gout flares
MX367255B (es) Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
SG195127A1 (en) Methods of treating or preventing neurological diseases
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
MX2015001488A (es) Tratamiento de la inflamacion utilizando serelaxina.
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
WO2014169011A3 (en) Methods for treating immune diseases
SG195170A1 (en) Methods of treating or preventing rheumatic disease
GB201022049D0 (en) Methods

Legal Events

Date Code Title Description
FG Grant or registration